ALKERMES | ALKS - الدائنين التجاريين





الدائنين التجاريين تغيير تاريخ
AbbVie USD 3.59B 28.65B 2025-12
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
ALKERMES USD 107.95M 39.95M 2025-12
Amgen USD 20.89B 1.25B 2025-12
Biogen USD 432M 18.9M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 4.29B 1.14B 2025-09
Coherus Biosciences USD 9.91M 14.98M 2025-12
Eli Lilly USD 5.38B 1.12B 2025-12
Gilead Sciences USD 808M 226M 2025-09
Heron Therapeutics USD 8.99M 3.02M 2025-12
Ionis Pharmaceuticals USD 14.33M 8.47M 2025-09
J&J USD 11.99B 2.37B 2025-12
Malin Corporation EUR 700K 200K 2024-12
Merck USD 4.15B 102M 2025-09
Minerva Neurosciences USD 640K 305K 2025-12
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Otsuka Holdings JPY 225.56B 31.54B 2025-12
Ovoca Bio EUR 186K 23K 2025-06
Pfizer USD 5.02B 142M 2025-09
Regeneron Pharmaceuticals USD 5.83B 4.93B 2025-12
Vertex Pharmaceuticals USD 3.43B 600.9M 2025-12